Targeted Complex Therapy for Advanced Melanoma and Gynecologic Cancers: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)

Trial Profile

Targeted Complex Therapy for Advanced Melanoma and Gynecologic Cancers: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)

Suspended
Phase of Trial: Phase I

Latest Information Update: 08 Feb 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Paclitaxel (Primary)
  • Indications Cervical cancer; Endometrial cancer; Fallopian tube cancer; Malignant melanoma; Ovarian cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Feb 2018 Planned End Date changed from 1 Jan 2018 to 1 Jun 2018.
    • 05 Feb 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jun 2018.
    • 11 Jul 2017 Status changed from recruiting to suspended due to melanoma cohort - per study design.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top